A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
NCT05680155 on ClinicalTrials.gov · last registry update 2025-09-10
A small phase 3 — 211 participants, against a typical 424. The sponsor logged completion for 12 June 2024. Primary outcome, as filed: Change from baseline in HbA1c. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- ecnoglutide
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 211
- Started
- 2022-12-29
- Primary completion
- 2024-06-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in HbA1c
Conditions studied
T2DM · Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.